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PEMBANGUNAN METHICILLIN RESISTANT STAPHYLOCOCCUS 
AUREUS (MRSA) BERPENDAFLUOR SEBAGAI SATU ALAT UNTUK  
PENYARINGAN CIRI-CIRI ANTIBAKTERIA MIMUSOPS ELENGI LINN. 
 
ABSTRAK 
 
 Staphylococcus aureus adalah sejenis bakteria Gram positif yang 
menyebabkan abses, beberapa jangkitan pyogenik (contohnya ‘endocarditis’ dan 
‘osteomyelitis’), keracunan makanan dan sindrom kejutan toksik. Ianya juga 
merupakan salah satu daripada penyebab jangkitan nosokomial (radang paru-paru, 
keracunan darah dan jangkitan luka pembedahan). “Methicillin Resistant 
Staphylococcus aureus” (MRSA) adalah salah satu strain yang menunjukkan 
kerintangan terhadap antibiotik β-laktam disebabkan oleh perubahan ke atas protein 
pengikat penicillin (penicillin binding protein) di dalam membran selnya. Secara 
lazimnya, semua antibiotik yang mempunyai ikatan β-laktam (β-lactam ring) seperti 
kumpulan penicillin dan ‘cephalosporin’ tidak berupaya untuk merencat aktiviti 
organisma ini. 
 Green fluorescent protein, GFP (protein berpendafluor hijau) adalah 
sejenis protein yang tidak diketahui fungsinya asalnya dan dijumpai di dalam sejenis 
obor-obor laut iaitu Aequorea victoria. GFP ini adalah sejenis protein yang boleh 
bergabung di dalam sitoplasma dengan menunjukkan tanda pola. Kajian ini akan 
memberi fokus ke atas pembangunan MRSA berpendafluor dengan membina MRSA 
yang membawa vektor gen GFP dengan bertujuan untuk menentukan samada MRSA 
berpendafluor boleh digunakan sebagai alat  untuk penyaringan segera ke atas ciri-
ciri antibakteria bagi sumber semulajadi. Sumber semulajadi yang  digunakan adalah 
 xix
ekstrak akuas dan ekstrak beberapa pelarut organik daripada batang tumbuhan 
Mimusops elengi Linn. atau dikenali sebagai pokok Bunga Tanjung. Beberapa kajian 
terdahulu menunjukkan pokok ini ada mempunyai  kandungan elemen antibakteria 
yang mujarab. Dalam kajian ini, penyelidikan fitokimia ke atas ekstrak akuas, dietil 
eter dan etil asetat daripada batang tumbuhan telah menunjukkan kehadiran 
komponen alkaloid, flavonoid dan tannin. Manakala, ekstrak dietil eter dan 
petroleum eter pula cuma menunjukkan kehadiran komponen alkaloid sahaja dan 
tidak menunjukkan kehadiran komponen flavonoid dan tanin. Kesemua metabolit 
sekunder ini diketahui disintesis sebagai kesan daripada tindakbalas terhadap infeksi 
mikrob. 
Oleh yang demikian, kajian ini telah dilakukan  untuk menyelidik potensi 
ekstrak batang M. elengi Linn. daripada akuas dan beberapa pelarut organic yang 
berbeza terhadap MRSA. Aktiviti antibakteria setiap ekstrak diuji untuk 
menunjukkan kepekatan kerencatan terendah (MICs) dan kepekatan bakterisidal 
terendah (MBC) yang boleh merencatkan pertumbuhan sehingga 99.9 % koloni 
bakteria ini.  
Ekstrak akuas, dietil eter dan etil asetat telah menunjukkan keputusan MIC 
(16 µg / ml) dan MBC (32 µg / ml) yang sama. Manakala, ekstrak etanolik dan 
petroleum menunjukkan keputusan MIC dan MBC yang lebih tinggi iaitu 32 µg / ml 
dan 64 µg / ml.  Hasil kajian menunjukkan bahawa kesemua ekstrak samada 
daripada akuas atau pelarut-pelarut organik menunjukkan aktiviti antibakteria 
terhadap MRSA. 
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DEVELOPMENT OF FLUORESCING METHICILLIN RESISTANT 
STAPHYLOCOCCUS AUREUS (MRSA) AS A TOOL FOR SCREENING OF 
ANTIBACTERIAL PROPERTIES OF MIMUSOPS ELENGI LINN. 
 
ABSTRACT 
 
Staphylococcus aureus is a Gram positive bacterium that can cause abscesses, 
various pyogenic infections (e.g. endocarditis and osteomyelitis), food poisoning and 
toxic-shock syndrome. It is also one of the most common causes of nosocomial 
infection (pneumoniae, septicaemia and surgical-wound infections). The Methicillin 
Resistant Staphylococcus aureus (MRSA) is a strain that is resistant to β-lactam 
antibiotic by virtue of changes in the penicillin-binding protein within their cell 
membrane. Consequently, all antibiotics that has β-lactam ring like penicillin group 
and cephalosporin group are unable to inhibit the growth of this organism.   
Green fluorescent protein (GFP) is a protein of unknown function found in 
the jellyfish,  Aequorea victoria. This GFP-fusion protein shows a punctuate pattern 
when localizes in the cytoplasm. The present study focused on the development of a 
fluorescing MRSA by the construction of MRSA vector carrying GFP gene with the 
intention of determining whether the fluorescing MRSA strain can be used as a tool 
for the rapid screening of antibacterial properties of natural product.  The natural 
products that had been used were aqueous and several organic solvents extracts from 
the bark of plant Mimusops elengi Linn. known locally as ‘Bunga Tanjung’ plant. 
This plant has been reported to contain a potent antibacterial component. In this 
study, phytochemical investigation of aqueous, ethanolic and  ethyl acetate extracts 
 xxi
of M. elengi Linn. revealed the presence of alkaloids, flavonoids and tannin 
compounds. Whereas, the diethyl ether and petroleum ether extracts revealed the 
presence of alkaloids only but absence of flavonoids and tannin compounds. These 
secondary metabolites are known to be synthesized in response to microbial 
infection.   
The present study is, therefore, designed to assess the antibacterial potency of 
different solvent extracts (aqueous, diethyl ether, ethyl acetate, ethanolic and 
petroleum ether) of the bark of M.  elengi Linn. on MRSA. The antibacterial activity 
of each extract was tested for their minimum inhibitory concentration (MIC) and 
minimum bactericidal concentration (MBC) which can inhibit the growth of at least 
99.9 % of the bacterial colonies.   
The aqueous, diethyl ether and ethyl acetate extracts had recorded the same 
results of MIC (16 µg / ml) and MBC (32 µg / ml) against MRSA. Whereas, the 
ethanolic and petroleum ether extracts had recorded higher results of MIC and MBC 
i.e. 32 µg / ml and 64 µg / ml against MRSA. These results showed that all aqueous 
and organic solvents extracts had antibacterial activities against MRSA. 
 
 
 
 1
 CHAPTER 1 
Introduction 
 
 
 
1.1 Background of  Staphylococcus aureus    
     
Staphylococcus aureus literally means "Golden Cluster Seed" and also known as 
golden staphylococcus, is the most common cause of Staphylococcus infections. The 
name "Staphylococcus" originates from the Greek word staphyle, meaning a bunch of 
grapes, and kokkos, meaning berry, and that is what Staphylococcus looks like under the 
microscope, like a bunch of grapes or little round berries as shown in Figure 1.1  
 
                                      
             Figure 1.1: Gram positive S. aureus under light microscope   
                                               (100 x oil objective)  
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   It is a spherical bacterium, frequently living on the skin or in the 
nose of a person. Approximately 20–30% of the general populations are 
"Staphylococcus carriers". S. aureus can cause a range of illnesses from minor skin 
infections, such as pimples, impetigo (may also be caused by Streptococcus pyogenes), 
boils, cellulitis, folliculitis, furuncles, carbuncles, scalded skin syndrome, wound 
infection and abscesses, to life-threatening diseases, such as pneumonia, meningitis, 
osteomyelitis,  endocarditis, Toxic Shock Syndrome (TSS), urinary tract infection (UTI) 
and septicemia. 
Its incidence is from skin, soft tissue, respiratory, bone, joint, endovascular to 
wound infections. It is still one of the four most common causes of nosocomial 
infections, often causing postsurgical wound infections. S. aureus was discovered in 
Aberdeen, Scotland in 1880 by the surgeon Sir Alexander Ogston in pus from surgical 
abscesses (Ogston, 1984). 
 
1.2 Microbiology of  S. aureus 
It is Gram positive cocci in cluster about 1 μm in diameter which appears as 
grape-like clusters when viewed through a microscope and has large about 6-8 mm in 
diameter, rounded and smooth, golden-yellow  or pale yellow to orange colonies (Figure 
1.2), often with  β-hemolysis, when grown on blood agar plates (Ryan and Ray, 2004) as 
shown in Figure 1.3. The golden appearance is the etymological root of the bacteria's 
name: aureus means "golden" in Latin.  
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                Figure 1.2: S. aureus on Blood Agar (BA) 
 
 
 
                     
     Figure 1.3: S.  aureus colonies with beta-hemolysis on BA. 
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 It is a facultative anaerobe, it grows in the air, but can also thrive in anaerobic 
conditions. It is an opportunistic pathogen,   it may be present in the body without 
causing any harm, but in  lowered immunity or injury, it may cause 
a disease. Staphylococci bacteria have no flagella, so they are immobile. They grow in 
pairs, short chains or clusters (Figure 1.1). Staphylococcus is in the Family 
Staphylococcaceae, which includes three other genera, Gamella, Macrococcus and 
Salinicoccus.  S.  aureus is catalase positive (meaning that it can produce the enzyme 
"catalase") and able to convert hydrogen peroxide (H2O2) to water and oxygen, which 
makes the catalase test useful to distinguish staphylococci from enterococci and 
streptococci. A large percentage of S. aureus can be differentiated from most other 
staphylococci by the coagulase test: S. aureus is primarily coagulase-positive (meaning 
that it can produce the enzyme "coagulase" that causes clot formation) while most other 
Staphylococcus species are coagulase-negative (Ryan and Ray, 2004). 
However, while the majority of S.  aureus are coagulase-positive, some may be 
atypical in that they do not produce coagulase. Incorrect identification of an isolate can 
impact implementation of effective treatment and or control measures (Matthews et al., 
1997). It is medically important to identify S. aureus correctly as S.  aureus is much 
more aggressive and likely to be antibiotic-resistant. S. aureus can grow at temperature 
range of 15 – 45ºC and at high salt concentrations as high as 15% and resistant to 
drying. It is a normal flora of the human and is found on the nasal passages, skin and 
mucous membranes.  
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S. aureus express many potential virulence factors such as surface protein that 
promote colonization of host tissues, invasions that promote bacterial spread in tissues 
(leukocidin, kinases, hyaluronidase), surface factors that inhibit phagocytic engulfment 
(capsule, Protein A), biochemical properties that enhance their survival in phagocytes 
(carotenoids, catalase production), immunological disguises (Protein A, coagulase, 
clotting factor), membrane-damaging toxins that lyse eukaryotic cell membranes 
(hemolysins, leukotoxin, leukocidin), exotoxins that damage host tissues or otherwise 
provoke symptoms of disease (SEA-G, TSST, ET) and inherent and acquired resistance 
to antimicrobial agents. 
1.3 The structure of  S.  aureus cell wall 
 S. aureus cell wall consists of three layers: outer polysaccharide 
capsule, peptidoglycan (murein) layer, and inner cytoplasmic membrane. Into this 
structure, proteins and teichoic acid are embedded and protrude from the cell wall on its 
outer side, forming a “fuzzy coat” (Figure 1.4). Capsule is thin but it can still survive 
outside the body, e.g. on bed lining or computer keyboards from few days to several 
weeks as has been reported by Hsu et al., (2005). This thin capsule may be seen only 
under the electron microscope. Sometimes more bacteria share one capsule and form a 
slime layer or biofilm, mostly found on the inner wall of venous and urinary catheters. 
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                         Figure 1.4: S. aureus cell wall structure 
               Adapted from www.healthhype.com/staphylococcus-aureus.html 
                                                (Cited on 10 / 09 / 2009) 
 
1.4 Epidemiology of S. aureus 
 The main primary reservoir for S. aureus, including MRSA, is the human. 
Staphylococcus is also common in cows, poultry and pets such as cats and dogs. In 
healthy people, especially  among S.  aureus carriers, Staphylococcus lives in the 
mucosa of the nose, less commonly in the throat, vagina, intestines and lungs, on the 
skin mainly in the armpits, under the breasts and in the groin. In infected people, 
Staphylococcus is common in skin lesions, blood, stool, urine, respiratory mucosa, 
genitals and abscesses of internal organs. It can be spread from one skin location to 
another, person to person spread via skin-on skin contact or with sharing toys, towel, 
sport equipment, public showers, sauna or swimming. Infection may also be spread by 
healthy staphylococci carriers especially by health personnel. Infection by milking a cow 
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with staphylococci mastitis is possible and staphylococci food poisoning may occur after 
ingesting food contaminated with staphylococci, released from an infected food worker. 
    Entry points of staphylococci infection are skin and respiratory tract. 
Examples of skin infection are acne, eczema, skin injury, burns, injection, vascular and 
urinary catheters and surgical wounds. For respiratory tract infection, staphylococci may 
cause staphylococcal pneumonia due to complication of influenza and aspiration. 
Incubation period of  S. aureus infection may vary a lot, but it is commonly between 4 to 
10 days. For staphylococci food poisoning, the incubation period is 30 minutes to 8 
hours.  
 
1.5 Diagnosis of  S. aureus infection 
Diagnosis of  S.  aureus infection is dependent on the type of infection that has 
occurred and that an appropriate specimen is obtained accordingly and send to the 
laboratory for definitive identification by using biochemical or enzyme-based tests. In 
most clinical microbiology laboratory, examination and identification is done by 
conventional culture, identification by biochemical identification and susceptibility test 
to detect the presence of MRSA. A Gram stain is first performed to show the presence 
of  typical gram-positive bacteria and cocci in clusters.  
Secondly, the organism should be cultured onto mannitol salt agar which is a 
selective medium with 7 – 9% NaCl that allows S.  aureus to grow producing yellow-
colored colonies as a result of mannitol fermentation. For differentiation at the species 
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level, the enzyme-based tests are to be performed. The tests are catalase (positive for all 
Staphylococcus species), coagulase (fibrin clot formation, positive for S. aureus), 
DNAse (zone of clearance on nutrient agar), lipase (a yellow colour and rancid odour 
smell) and phosphatase (a pink colour). Other tests are rapid diagnosis with polymerase 
chain reaction (PCR) and S.  aureus detection kit such as the Oxoid penicillin-Binding 
Protein Latex  Agglutination Test. 
A number of studies have examined the use of molecular methods for direct 
detection of MRSA in blood culture positive in order to facilitate rapid diagnosis of 
MRSA and enable appropriate therapeutic decisions to be made in a timely manner. 
Such methods are gel-based and real-time PCR, DNA probes and peptide nucleic acid 
probes. Rapid and precise identification of MRSA is a prerequisite for control of 
hospital infections. Molecular methods require much less time than conventional 
microbiological methods, therefore, it can provide not only a considerable advantage 
with respect to reliability but also in speed. 
 
1.6 Treatment of S.  aureus infection 
The choice of treatment for S. aureus is penicillin, but in most countries, 
penicillin - resistance is extremely common and first-line therapy is most commonly a 
penicillinase - resistant penicillin (for example, oxacillin or flucloxacillin). Combination 
therapy with gentamicin may be used to treat serious infections like endocarditis (Bayer 
et al., 1998) but its use is controversial because of the high risk of damage to the kidneys 
(Cosgrove et al., 2009).  
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Staphylococcal colonization may be treated with mupirocin nasal gel and daily 
Hibiclens skin cleanser baths. Local skin infections are treated with antibacterial 
ointments. In more extensive infections, S.  aureus has to be tested for antibiotic 
sensitivity and then usually oral antibiotics are used. In systemic infection, 
hospitalization and intravenous antibiotics are needed. Severe staphylococcal infections 
require treatment with parenteral penicillinase-resistant penicillin like nafcillin and 
oxacillin or cephalosporin of 1st or 2nd generation (e.g. cephalexin, cefuroxime) plus 
clindamycin. Vancomycin is reserved for MRSA and clindamycin resistant strains or for 
life-threatening infections. Staphylococcal food poisoning usually heals on its own.  
 
1.7 Staphylococcus antibiotic resistance 
Antibiotic resistance in  S.  aureus was almost unknown when penicillin was first 
introduced in 1943. Indeed, the original petri dish on which Alexander Fleming of 
Imperial College London observed the antibacterial activity of the penicillium mould 
also showed growth of a culture of S. aureus. By 1950, 40% of hospital’s S. aureus 
isolates were penicillin resistant, and by 1960, this had risen to 80 % (Chambers, 2001). 
Hospital strains of S. aureus are usually resistant to a variety of different 
antibiotics. In 1945, only two years after the introduction of penicillin in infection 
treatment, staphylococcus resistance to penicillin was recognized in hospitals. In 1960, 
methicillin (later replaced by oxacillin) was used to treat penicillin resistant 
Staphylococcus leading to the emerging of MRSA strains to the worldwide. In 1961, the 
first MRSA case was reported. Over 90% of staphylococci now contain the enzyme 
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penicillase (an enzyme in a form of β-lactamase which breaks down the β-lactam ring of 
the penicillin molecule) so staphylococci have to be treated with penicillinase-resistant 
penicillins, cephalosporins or other antibiotics.  
MRSA is resistant to most antibiotics derived from penicillin, including 
methicillin, nafcillin, oxacillin, cloxacillin, dicloxacillin and flucloxacillin. 
Staphylococci have two mechanisms for resistance to beta-lactam antibiotics. One is the 
production of beta-lactamases, enzymes that hydrolytically destroy the beta-lactam ring. 
The other is the expression of an exogenous gene, mecA that encodes an additional 
penicillin-binding protein 2a (PBP 2a or PBP 2’), which is not susceptible to inhibition 
by beta-lactam antibiotics. This mecA gene is carried by a mobile genetic element, 
designated Staphylococcal Cassette Chromosome mec (SCC mec), inserted near the 
chromosomal origin of replication of staphylococcus which confers resistance to all 
currently available beta-lactam agents antibiotic such as penicillins, cephalosporins and 
carbepenems and this resistance obviates their clinical use during MRSA infections. 
Methicillin-resistant isolates with alteration to existing PBPs have been described. These 
isolates have been termed ‘moderately resistant S. aureus’ (MODSA) and ‘borderline 
oxacillin-resistant S. aureus’ (BORSA), which produced large amounts of penicillinase 
(a form of β-lactamase). In United Kingdom, only  2%  of all  S.  aureus isolates are 
sensitive to penicillin with a similar picture in the rest of the world, due to penicillinase. 
Today, S.  aureus has become resistant to many commonly used antibiotics and 
are susceptible only to glycopeptides antibiotics such as vancomycin and investigational 
drugs. However, with the worldwide emergence of glycopeptides intermediate S.  aureus 
(GISA) or also known as vancomycin-intermediate S. aureus (VISA) strains with 
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vancomycin MICs of 8 or 16 µg / ml (Chui and Hiramatsu, 2003; Hiramatsu, 1997), the 
likelihood of this resistance reaching global magnitude causes great concern about the 
possibility of losing the last treatment option for multidrug resistant staphylococcus 
infection (Cui et al., 2005). MRSA is now a problem in hospitals worldwide and is 
increasingly recovered from nursing homes and the community. 
 In Malaysia, even though the MRSA incidence rate is still less than 0.5% 
(according to the National Nosocomial Infection and Infection Control Report for the 
year of 2008 by Ministry of Health) but shows an increasing trend over five years 
period.  This has fostered a sense of urgency with regards to need of acquiring new 
drugs. 
 
1.8  Infection control of S.  aureus 
Spread of S. aureus including MRSA is through human-to-human contact 
although recently some veterinarians have discovered that the infection can be spread 
through pets. Emphasis on basic hand washing techniques are therefore effective in 
preventing the transmission of S.  aureus. The use of disposable aprons and gloves by 
staff reduces skin-to skin contact and therefore further reduces the risk of transmission. 
S.  aureus has had facilitated transportation in medical facilities mainly because 
of insufficient healthcare worker hygiene. Therefore, all the surfaces of equipments in 
hospitals should be cleaned with alcohol, quaternary ammonium or iodine compounds, 
which are effective against methicillin sensitive S. aureus (MSSA) and MRSA. Effective 
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sprays for air disinfection also exist. In March 2007, the BBC reported that a vaporizer 
spraying some essential oils (including tea tree oil) into the atmosphere reduced airborne 
bacterial counts by 90% and kept MRSA infections at bay and may hold promise in 
MRSA infection control. 
S. aureus is a major cause of Hospital Acquired Infection (Nosocomial Infection) 
of surgical wounds and infections associated with indwelling medical devices. The 
reservoir of MRSA is in infected and colonized patients and the major mode of 
transmission from patient to patient is on the contaminated hands of healthcare workers. 
Laboratory diagnosis and susceptibility testing are crucial steps in treating, controlling 
and preventing MRSA infection. MRSA can be life-threatening to patients with deep 
wounds on intravenous catheters or other foreign-body instrumentation, or as a 
secondary infection in patients with compromised immune systems. 
 
1.9  New drug discovery from natural product. 
Modern medicine is engaged in an eager quest for new antibiotics, which can 
treat the infections caused by constantly emerging antibiotic resistant bacteria 
(Rangaman et al., 2007). The limited life span of antimicrobial is due to resistance 
developing by indiscriminate use which necessitates the continuous search for 
alternatives. Awareness for misuse of antibiotics and also the potential risk of using 
synthetic form of phytochemicals have been reported (Borris, 1996). 
Nature has been a source of medicinal agents for thousands of years and an 
impressive number of modern drugs have been isolated from natural sources, many 
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based on their use in traditional medicine. The use of traditional plant extracts as well as 
other alternative forms of medical treatments have been gathering momentum since 
1990s (Cowan, 1999). Recent research has identified plants as a promising source of 
natural antibiotics against various pathogenic microorganisms (Rangaman et al., 2007). 
In this respect, plants used in traditional medicinal systems have been proven to be a 
reliable source. Being secondary metabolites, the production of these antibiotic 
compounds by plants are affected by various stress conditions experienced by the plants. 
Traditionally common people use crude extracts of plant parts as curative agents 
(Mendoza et al., 1997; Sanches et al., 2005).  
Malaysia is a country that is rich in natural products which have great potential 
in possessing antimicrobial properties. Some of these natural products might have 
antimicrobial properties against MRSA. However, high-throughput screening of new 
antimicrobial agents require the development of rapid, inexpensive screening system 
such as the use of fluorescent recombinant bacteria expressing green fluorescent protein 
(GFP). High-throughtput screening is defined as a process for rapid assessment of 
activity in samples, usually derived from a combinatorial library or other compound 
collection. It allows drug screening test in a short period of time through a combination 
of modern robotic, data processing and control software, liquid handling devices and 
sensitive detectors.  
The present study will focus on the development of a fluorescing MRSA by the 
construction of MRSA carrying green fluorescent protein with the intention of 
determining whether the MRSA strain can be used as a tool for rapid screening of 
antibacterial properties of natural product. Rapid screening of antibacterial properties 
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from natural product allows drug screening in a short period of time and may reduce the 
misuse and resistance of the antibiotics in population. 
 
1.10 Mimusops elengi Linn. 
M. elengi Linn. belongs to the family Sapotaceae. It is an evergreen tree, 5 – 8 
metre tall (Figure 1.5). It is cultivated throughout as an ornamental tree. Medicinal 
properties of     M. elengi Linn., a common tree species in Malaysia, is not very well 
known. Phytochemical investigation of the plants reveals that the bark decoction, 
flowers (Figure 1.6) and fruits (Figure 1.7) are used as teeth cleaner and tender twigs are 
used as tootbrush (Dymock et al., 1981) and the extract of the seed had showed good 
antimicrobial activity (Hazra et al., 2007) and are used in constipation (Nair & Chanda, 
2007). 
 In India, the bark (Figure 1.8) is used as gargle for odontopathy, ulitis and 
ulemorrhagia (Abbas et al., 2008). The fruits are used as astringent, coolant and 
antihelmintic whereas the tender stems are used as tooth brushes and in cystorrhea, 
diarrhea and dysentery (Abbas et al., 2008). The flowers’ lotion is used for wounds and 
ulcers (Nair and Chanda, 2007). In  Indonesia, the M.  elengi Linn. leaves are often used 
as traditional medicine for asthma, mouth and throat infections (Susan et al., 2006). Due 
to the fact that the plant M.  elengi Linn. is very useful, as found by above mentioned 
reports and the fact that little information cited in the literature (Nair and Chanda, 2007; 
Hazra et al., 2007; Mohamed et al., 1996 and Sahu et al., 2001) is available on the 
biological activities, there is a need to find out more about the potentiality of this plant 
as an antimicrobial agent.  
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The present study is, therefore, designed to assess the potency of different 
solvent extracts of M. elengi Linn. on MRSA. The antibacterial activity of each extract 
was tested for their minimum inhibitory concentrations (MICs) using the MIC broth 
macrodilution method (Jorgensen & Turnidge, 2005; Andrews, 2001) and minimum 
bactericidal concentrations (MBCs) to determine the concentration of drug that inhibits 
at least 99.9 % of the bacterial colonies. 
                                          
                   Figure 1.5:  M.  elengi Linn. plant (pokok Bunga Tanjung). 
    
                                         
                                      Figure 1.6: The flowers of M. elengi Linn. 
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                Figure 1.7: The fruits of M.  elengi Linn. 
     
 
                                    
           Figure 1.8: The bark  of M.  elengi Linn. 
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 1.11 Green fluorescent protein (GFP) 
 The green fluorescent protein (GFP) is a protein composed of 238 amino acids 
(26.9kDa), which exhibits bright green fluorescence when exposed to blue light. 
Although many other marine organisms have similar green fluorescent proteins, GFP 
traditionally refers to the protein first isolated from the jellyfish Aequorea victoria.  
 
 GFP was first discovered in 1961 by Osamu Shimomura et al. (Tsein, 1998). 
GFP produces an intense and stable non-catalying green fluorescence by absorbing blue 
light maximally at 395 nm and emitting green light with peak at 509 nm (Chalfie et al., 
1994). This process takes place when the protein aequorin, also produced by A. victoria, 
interacts with Ca2+ ions thus emitting a blue glow (Shimomura et al., 1962; Morin & 
Hasting, 1971; Ward et al., 1980). 
 
GFP folds into a unique, compact structure known as β-can that is strongly 
resistant to chemical denaturation and found to be stable in most cells (Corish and Tyle-
Smith, 1999). The β-can structure encloses an α-helix containing the chromophore 
(Figure 1.9). This structure is required to provide a proper environment for the 
chromophore to fluoresce as shown by the fact that nascent GFP do not fluoresce 
(Clontech, 2001).  GFP fluorescence occurs without any cofactors and this property 
allows GFP fluorescence to be utilized as a reporter in non-native organism. 
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       Figure 1.9: Structure of the A. victoria green fluorescent protein. 
                                     Image from Yang et al. (1996). 
 
 The fluorescence is derived from post-translatinonal cyclization of a serine-
tyrosine-glycine tripeptide of the GFP protein, followed by dehydrogenation of the 
tyrosine. It is generated by sequential activation of two photon proteins, aequorin and 
GFP. Upon calcium binding, aequorin emits blue light which in turn excites GFP to 
fluoresce. GFP produces green fluorescence which requires only the presence of oxygen 
to maturate with no external compounds needed (Andersen et al., 1998; Chalfie et al., 
1994). 
 The cloning of the wild-type GFP gene (Prasher et al., 1992; Inouye & Tsuji, 
1994) and its subsequent expression in heterologous systems (Chalfie et al., 1994) 
established GFP as a novel genetic reporter system. Its adaptation for microbial studies 
led to the development of optimised, more soluble, brighter, blue or red-shifted mutants 
extending potential applications (Cormack et al., 1996; Crameri et al., 1996; Heim et al., 
1994). 
GFP has become popular reporter system for use in both prokaryotes and 
eukaryotes. In eukaryotes, it has been used in numerous applications, including 
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transcriptional protein fusions to study protein targeting (Cowley and Av-Gay, 2001). In 
prokaryotes, it has been used primarily as a reporter for promoter activity by creating 
transcriptional fusions in a wide range of bacterial species, including S.  aureus (Cui et 
al., 2005), Escherichia coli, Brucella suis, Salmonella typhimurium and Mycobacterium 
spp. (Dhandayuthapani et al., 1995, Valdivia et al., 1996).  In modified form, it has been 
used to make biosensors. GFP generally does not interfere with the growth of the host 
and thus it is an excellent choice for non-disruptive studies of bacterial communities or 
other systems, which require live cells to be studied at the single cell level (Clontech, 
2001).  
 
1.12  Recombinant Staphylococcal Expressing GFP 
The utilization of GFP has been extended by modification of the GFP structure 
by mutating and re-constructing the GFP gene. There are several variants of GFP which 
has been introduced such as UV-optimized GFP (GFPuv), GFP excitation (enhanced 
green fluorescent protein, EGFP- e.g. GFPmut1) and GFP emission (enhanced yellow 
fluorescent protein, EYFP and enhanced cyan fluorescent protein, ECFP). These variants 
are able to fluoresce more intensely compared to the original wild type GFP (wtGFP) 
(Clontech, 2001). 
 The GFPuv had been widely used as a reporter for studying the genetic basis for 
virulence in S.  aureus (Bateman et al., 2001). In another study by Schneider et al. 
(2002), the GFP had been used in differential fluorescence induction (DFI) assay in an 
effort to identify S.  aureus gene whose products can be targeted for antimicrobial drug 
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development. Wamel et al. (2002) had used green fluorescent protein reporter gene 
system to examine the expression and growth regulation of the capsular polysaccharide 
5 genes by two major global regulator of  S.  aureus (agr and sarA) in vitro and in a 
rabbit endocarditis model. 
The reporter vector expressing green fluorescent protein under the control of 
xylose-inducible promoter had been constructed to be used in the comparative studies of 
antisense effects in   S.  aureus (Nekhotiaeva et al., 2004). This antisense approach had 
been developed to improve understanding of the genetic and environmental requirement 
for  S. aureus  growth and pathogenesis. It is important to understand the  S.  aureus 
growth and pathogenesis because of the emergence and spread of vancomycin-resistant 
S. aureus strains and therefore highlight the need for new strategies in therapeutic 
development. 
Frank et al. (2005) had used the green fluorescent protein variant (gfpmut3.1 
from Clontech) as a reporter gene system in S.  epidermidis. In a study by Cui et al. 
(2005), the green fluorescent protein had been used as a transcriptional fusion system in 
identification of gene associated with glycopeptides resistance in S.  aureus. A study by 
Grundling and Schneewind (2006) had used purified GFP fused to C-terminal cell wall-
targeting domain to reveal species-specific association of the reporter with 
staphylococci. The recent study by Jamie et al. (2009) had used S.  aureus-expressing 
cytolisis GFP to provide a novel probe of the fate of S. aureus in human 
polymorphonuclear leukocytes (PMN). 
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These studies suggest that GFP is a useful reporter of viability in staphylococci 
and furthermore it has been used for antibacterial screening and survival study of 
staphylococci towards PMN action. However, the use of pathogenic or even 
opportunistic staphylococci for screening assays raises safety concerns.  
 
1.13 Rational of study 
 MRSA is an important nosocomial pathogen that exhibit resistance to a wide 
range of antibiotic drugs. The spread, survival and prevalence of antibiotic resistant 
clones of S. aureus are immensely important problems for human health. The rapid and 
accurate identification of the disease causing agent is therefore a prerequisite for disease 
control as well as for epidemiological surveillance. Thus, there is a need to screen new 
anti-MRSA compounds that requires the development of a rapid and inexpensive assay 
method. Therefore, the development of fluorescing MRSA as a tool for rapid screening 
of  antibacterial  properties of M. elengi Linn. is one of inexpensive screening systems 
that allows drug screening in a short period of time and may reduce the antibiotics 
resistance in population.  
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1.14  Objectives of the study 
The main objective of this study is to develop a recombinant plasmid that  
can be used to express GFP at an optimum level in MRSA. The fluorescent recombinant 
MRSA strain can then be used in rapid screening system for evaluating the antibacterial 
properties of natural product such as the bark of M.  elengi Linn. 
To achieve this objective, the following specific aims will be carried out: 
1. To construct the E. coli - S. aureus shuttle vector that can be used for 
transformation and expression of GFPuv in   E. coli   and   S.  aureus. 
2. To investigate the antibacterial properties of different solvent extracts of           
M. elengi Linn. on   MRSA. 
3. To analyze the phytochemical and antibacterial properties of M. elengi   Linn. 
extracts in different solvents.  
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1.15  Experimental overview 
 
PART 1      PART 2 
Construction of plasmid expressing        Screening antibacterial properties     
GFP                                  of M.  elengi Linn. 
 
· pRIT5ds-as a backbone    Extraction with water and  
. plac-gfpuv- as an insert    other solvents 
 
 
 
 
Ligation of pRIT5ds and    Extraction     Testing the 
plac-gfpuv     analysis by     extracts for 
Thin Layer     antibacterial 
Chromatography            properties by using  
and GC-MS                    fluorescing MRSA 
 
 
Transformation into E.  coli TOP10F’ 
 
 
 
 
Plasmid extraction 
 
 
 
 
Transformation of  the plasmid      
pRITDds-plac-gfpuv into MRSA 
by electroporation 
 
 
 
Protein analysis by   Evaluate and testing the fluorescing MRSA 
SDS-PAGE    as a rapid tool for screening of antibacterial 
     properties of M.  elengi Linn. 
 
 
Figure 1.10: Flow chart of experimental overview 
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CHAPTER 2 
MATERIALS AND METHODS 
 
 
 
2.1 Materials 
 
2.1.1 Bacterial strains 
 
The list of bacterial strains used in this study is shown in Table 2.1.  
 E. coli TOP10F’ strains are grown at 37˚C in the Luria-Bertani (LB) medium 
whereas MRSA are grown at 37˚C in B2 medium (refer page 28). For a longer 
period of storage, cells were maintained in the form of glycerol stocks and stored 
at -80˚C. 
 
Table 2.1 List of bacterial strains used in this study  
Bacterial species and strains Source 
E. coli TOP10F’ 
 
Invitrogen, USA 
MRSA 
           ATCC 700698 
 
           MR 352 
 
 
Institute for Medical Research (IMR) 
 
Stock culture from clinical sample, 
Department of Medical Microbiology 
and Parasitology, School of Medical 
Sciences, Universiti Sains Malaysia 
 
MSSA 
           BL 92 
 
Stock culture from clinical sample, 
Department of Medical Microbiology 
and Parasitology, School of Medical 
Sciences, Universiti Sains Malaysia 
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2.1.2 Plasmids 
 
The plasmids used in the study are pGFPuvk supplied by Becton 
Dickinson Bioscience Clontech and pRIT5ds-gfp was a gift from by Cui et al. 
(2005). The maps of the plasmids are shown in Figure 2.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     pGFPuvk 
    4341bp 
Kan R
GFPuvpUC Ori 
PstI 6275 
     pRIT5dS-gfp
6466 bp
EcoRI 5521
BamHI 5631
AmpR
CATgfp
Figure 2.1: Maps of pGFPuvk plasmid and pIT5ds-gfp plasmid 
         
